More and more 3D printing technology is used in the field of heart disease treatment. After applying to the left atrial appendage in several top three hospitals in Shanghai last year, Beijing Fuwai Hospital successfully applied it to other treatment areas of congenital heart disease. Recently, Prof. Zheng Hong from the Department of Interventional Radiology of Fuwai Cardiovascular Hospital led his interventional team to successfully perform a occlusion procedure on a patient with a lower atrial septal defect, which broke the lower atrial septal defect and could not be treated with interventional therapy. Taboos prevent many patients with congenital heart disease from suffering from open surgery. Professor Zheng Hong’s secret weapon is 3D printing technology. 3D printing technology has been applied in the field of medical devices a few years ago. It can directly generate organ structures and print out stereoscopic models. Doctors can judge and implement complex operations. The patient's heart surgery is very complicated, and the doctor needs to select the appropriate type of medical device according to the needs. Before the operation, the patient's heart model is printed, the doctor can make a more accurate judgment on the patient's heart structure, research and select the PDA occluder to be placed, and the skillful technology can greatly improve the treatment success rate. A lot of surgery that was impossible was possible. At present, 3D printing technology is mainly used in the field of heart disease, which has an unexpected promotion effect on the diagnosis and treatment of structural heart disease, especially complex congenital heart disease. 3D printing technology has made many diseases (especially structural heart disease) enter Personalized treatment is the era of “private customizationâ€. According to the reporter, since 2009, Professor Zheng Hong has been paying attention to the development of 3D printing technology. Since 2012, 16 cases of complex and special congenital heart disease, cardiomyopathy and left atrial appendage have been completed, according to digital imaging. 3D printing model design, application and acquisition of patents such as congenital heart disease and left atrial appendage occluder, and completed the first "three-dimensional printing guide under the guidance of 3D printing" in November 2013 and September 2014 After the interventional treatment of rupture of aortic sinus aneurysm and "3DP technical guidance using PDA occluder intervention for the treatment of inferior cavity ASD", the latter was proved to be the world's first by the Beijing Science and Technology Information Institute. As one of the drafters of China's “13th Five-Year Strategic Research Planning Task†– application and strategic planning of 3D printing technology in cardiovascular disease, Professor Zheng Hong believes that the foundation of the first and second levels of 3D printing should be consolidated. In the application of 3D printing technology for cardiovascular diseases, establish a digital model library of cardiovascular diseases, especially structural heart diseases, to make up for the defects of insufficient autopsy sources. The establishment of this library can bring precision and best to each patient. The treatment plan can also become a real "physical specimen" and training tool for doctors such as surgery and interventional departments to learn about various cardiovascular malformations. In addition, combining digital models of complex structural heart disease with Internet technology can make telemedicine technology a higher level and make cardiovascular disease diagnosis and treatment easier and more convenient. Zheng Hong pointed out that the highest level of 3D printing technology is to create human organ substitutes through cell and tissue 3D printing, such as active and functional blood vessels, valves and even the heart and other tissues. As the third level of 3D printing of cells and organizations, China should set up its own superior team, and closely follow the research progress of developed countries in this respect, and obtain the latest technology through various channels such as study abroad, visit, exchange and cooperation. Learning, improving and independent innovation achieve the goal of getting twice the result with half the effort. Raw materials for animal medicine Conventional veterinary drug raw materials are: oxytetracycline hydrochloride, doxycycline, chlortetracycline hydrochloride, lincomycin sulfate, gentamycin sulfate, tylosin tartrate, florfenicol, water-soluble amoxicillin, sulfamethoxazole, enno Floxacin lactate, ciprofloxacin hydrochloride, ciprofloxacin hydrochloride, metronidazole, ribavirin, vitamin C, astragalus polysaccharide, penicillin potassium. Raw materials for animal medicine,Nicarbazin in Feeds,Nosiheptide Veterinary,Nosiheptide Antibacterial,Human Gastric Mucin Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikang.com
The traditional Chinese medicine extracts in veterinary medicines are derived from natural Chinese herbal medicines.
It is purified, concentrated and purified in a different ratio from the original drug. It not only retains the natural state and biological activity of the original drug composition structure, but also retains the harmless and
The beneficial exogenous substance essence realizes the micro-quantification and standardization of Chinese herbal medicine raw materials, and provides a new way for the breeding industry to realize green production. The following herbal extracts for veterinary use: Anti-pathogenic microorganisms Chinese medicine: Anything that can inhibit or kill the reproduction of pathogenic microorganisms and improve the immunity of the body is called anti-pathogenic microorganisms
Chinese herbal medicine. According to the theory of traditional Chinese medicine, it can be divided into heat-clearing medicines, exopathic medicines, diarrhea and water-repelling medicines, damp-damping and diuretic medicines, phlegm-relieving and cough-relieving medicines, qi-regulating and Xiao-shi pharmacological blood medicines, and phlegm-relieving and anti-asthmatic medicines.